On February 1, 2024, Acumen Pharmaceuticals, Inc. announced that James Doherty has been appointed as its President and Chief Development Officer, effective February 1, 2024. Effective upon the commencement of Mr. Doherty?s employment, Daniel O?Connell?s position would be updated to Chief Executive Officer. Mr. O?Connell was previously the Company?s Chief Executive Officer and President.

Mr. Doherty, age 56, was most recently the Chief Development Officer at Sage Therapeutics, Inc. (? Sage Therapeutics ?) from October 2021 to January 2024. Prior to October 2021, Mr. Doherty held several positions at Sage Therapeutics, including as Chief Research Officer from December 2016 to October 2021.

Previously, he served as Director and Head of the Neuroscience Department for the Central Nervous System and Pain Innovative Medicines Unit of AstraZeneca Pharmaceuticals in Sodertalje, Sweden, where he led the company?s research pipeline for Alzheimer?s disease and neurodegeneration. Prior to that, he served as Director and Head of the Neuroscience Department at AstraZeneca in Wilmington, Delaware. Mr. Doherty holds a B.A. in Biology from the University of Delaware and received his Ph.D. in Neurobiology from Georgetown University.